Le Lézard
Classified in: Covid-19 virus
Subjects: AWD, NPT, REL, DEI

2022 Genesis Prize Laureate Albert Bourla Receives Top Civilian Honor from Greece


Following the "Jewish Nobel" awarded to Bourla earlier this year, the Hellenic Republic marks the Pfizer CEO's contribution to fighting COVID-19 and saving lives

NEW YORK, April 11, 2022 /PRNewswire/ -- On April 5, 2022, Chairman and CEO of Pfizer Albert Bourla was honored with Greece's top civilian award for his efforts in developing a life-saving COVID-19 vaccine. Greek President Katerina Sakellaropoulou presented Dr. Bourla with the Golden Cross of the Order of the Redeemer, the oldest and the highest decoration of the Greek state, awarded for exceptional service in political, economic and humanitarian areas.

Greek President Katerina Sakellaropoulou (R) awards the medal of the Golden Cross of the Order of the Redeemer, to Pfizer President and CEO Albert Bourla (L), at a special ceremony at the Presidential Palace, Athens, Greece. [ALEXANDER BELTES/EPA]

This is the second high-level honor awarded to Dr. Bourla this year. Earlier in January, Albert Bourla was announced as the Laureate of the 2022 Genesis Prize, also known as the "Jewish Nobel". The Prize recognizes Bourla's leadership in delivering a safe and effective COVID-19 vaccine in record time, which saved millions of lives in the midst of the pandemic, as well as his commitment to his Jewish identity and the State of Israel.

The President of Israel Isaac Herzog will present the Genesis Prize to Dr. Bourla at a ceremony in Jerusalem on June 29.

Born in Thessaloniki, Greece, Dr. Bourla was raised in a family of Holocaust survivors. His parents were among the few left alive among the city's ancient Jewish community almost completely wiped out by the Nazis. Dr. Bourla asked The Genesis Prize Foundation to direct his $1 million prize award to projects aimed at preserving the memory of the victims of the Holocaust in Thessaloniki.

"Two important awards announced this year ? Greek and Jewish ? attest to the extraordinary achievement of Dr. Bourla and the Pfizer team, which he led during the worst public health crisis in over 100 years," said Stan Polovets, Founder and Chairman of The Genesis Prize Foundation. "Taking great risks, they gave the world a life-saving vaccine in record time ? months rather than years. We look forward to celebrating Dr. Bourla and this historic achievement in Jerusalem in June."

About the Genesis Prize

The Genesis Prize is a global award that celebrates Jewish achievement and contribution to humanity. As the 9th Genesis Prize Laureate, Dr. Bourla follows filmmaker and philanthropist Steven Spielberg, who was awarded the Genesis Prize in 2021, and the legendary human rights activist Natan Sharansky, the 2020 Laureate.

All previous Laureates have re-gifted their award to philanthropic causes about which they are passionate. Since inception in 2013, The Genesis Prize has raised matching funds, leveraging the annual $1 million award into philanthropic initiatives totaling $45 million, with grants going to 197 nonprofit programs in 31 countries, directly impacting the lives of tens of thousands of people. 

Photo - https://mma.prnewswire.com/media/1793975/Dr__Bourla_and_President_Sakellaropoulou___Alexander_Beltes_EPA.jpg  


These press releases may also interest you

at 09:05
ProStar Holdings Inc., ("ProStar®" or "the Company") , a world leader in Precision Mapping Solutions, is pleased to announce the following corporate update from Page Tucker, CEO. Dear Fellow Shareholders: Prostar has made significant...

at 09:00
Vox Royalty Corp. ("Vox" or the "Company"), a returns focused mining royalty company, is pleased to announce that it has completed the acquisition of an advanced portfolio of four Australian royalties at various stages of...

at 08:50
The "Global Potash Market: Analysis By Production Capacity, By Demand, By Mined Production, By Product Type, By End-Use, By Form, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to...

at 08:35
Canada Carbon Inc. (the "Company") is pleased to announce the closing of a non-brokered private placement of 7,500,000 flow-through units (each, a "FT Unit") at a price of $0.06 per FT Unit gross proceeds of $450,000 (the "FT...

at 08:31
Agile Premium Finance, a division of First Financial Bank, has integrated new capabilities through its partnership with ePayPolicy to simplify premium financing payments for clients in the insurance industry.  With ePayPolicy's latest feature...

at 08:30
The "Protein Expression Market - A Global and Regional Analysis: Focus on Application, End User, Product, Expression System, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global...



News published on and distributed by: